{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:20:17Z","timestamp":1790616017236,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.radonc.2022.03.019","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T03:12:03Z","timestamp":1649041923000},"page":"43-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["High dose rate brachytherapy in the management of anal cancer: A review"],"prefix":"10.1016","volume":"171","author":[{"given":"Zakariya S.","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paveen","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K.W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep S.","family":"Taggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2022.03.019_b0005","unstructured":"Anon. National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975-2014. SEER Cancer Stat. Rev. 1975-2014. 2018."},{"key":"10.1016\/j.radonc.2022.03.019_b0010","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines","volume":"107","author":"Saraiya","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2022.03.019_b0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.03.019_b0020","first-page":"1689","article-title":"A mixed-method study on the generic and ostomy-specific quality of life of cancer and non-cancer ostomy patients","volume":"23","author":"Jansen","year":"2015","journal-title":"Support care cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.radonc.2022.03.019_b0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF02054222","article-title":"Quality of life in colorectal cancer. Stoma vs. nonstoma patients","volume":"38","author":"Sprangers","year":"1995","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.radonc.2022.03.019_b0030","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.radonc.2014.04.013","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"111","author":"Glynne-Jones","year":"2014","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2022.03.019_b0035","doi-asserted-by":"crossref","first-page":"20181006","DOI":"10.1259\/bjr.20181006","article-title":"Anal cancer chemoradiotherapy outcome prediction using (18)F-fluorodeoxyglucose positron emission tomography and clinicopathological factors","volume":"92","author":"Rusten","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2022.03.019_b0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clon.2015.10.012","article-title":"Rectal Radiotherapy\u2013Intensity-modulated Radiotherapy Delivery, Delineation and Doses","volume":"28","author":"Teoh","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2022.03.019_b0045","series-title":"The GEC ESTRO Handbook of Brachytherapy","first-page":"3","article-title":"Rectal cancer","author":"Sun Myint","year":"2014"},{"key":"10.1016\/j.radonc.2022.03.019_b0050","first-page":"48","article-title":"The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"P\u00f6tter","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.03.019_b0055","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2014.08.027","article-title":"Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy","volume":"135","author":"Rijkmans","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2022.03.019_b0060","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5114\/jcb.2018.76884","article-title":"Brachytherapy boost after chemoradiation in anal cancer: a systematic review","volume":"10","author":"Frakulli","year":"2018","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.radonc.2022.03.019_b0065","doi-asserted-by":"crossref","unstructured":"M.J. Page D. Moher P.M. Bossuyt I. Boutron T.C. Hoffmann C.D. Mulrow et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews n160 n160.","DOI":"10.1136\/bmj.n160"},{"key":"10.1016\/j.radonc.2022.03.019_b0070","doi-asserted-by":"crossref","unstructured":"M.J. Page J.E. McKenzie P.M. Bossuyt I. Boutron T.C. Hoffmann C.D. Mulrow et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews n71 n71.","DOI":"10.1136\/bmj.n71"},{"key":"10.1016\/j.radonc.2022.03.019_b0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2017.05.023","article-title":"High-Dose-Rate Brachytherapy in the Management of Operable Rectal Cancer: A Systematic Review","volume":"99","author":"Buckley","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.03.019_b0080","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.brachy.2007.02.152","article-title":"Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma","volume":"6","author":"Oehler-J\u00e4nne","year":"2007","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2022.03.019_b0085","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.radonc.2008.04.011","article-title":"The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer","volume":"87","author":"Saarilahti","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.03.019_b0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/02841867809127689","article-title":"The Paris system in interstitial radiation therapy","volume":"17","author":"Pierquin","year":"1978","journal-title":"Acta Radiol Oncol Radiat Phys Biol"},{"key":"10.1016\/j.radonc.2022.03.019_b0095","doi-asserted-by":"crossref","first-page":"522","DOI":"10.5114\/jcb.2018.81025","article-title":"Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal","volume":"10","author":"Bertin","year":"2018","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.radonc.2022.03.019_b0100","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.brachy.2019.08.005","article-title":"High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers","volume":"18","author":"Varela Cagetti","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2022.03.019_b0105","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.brachy.2013.09.006","article-title":"Dosimetric and clinical outcome in image-based high-dose-rate interstitial brachytherapy for anal cancer","volume":"13","author":"Kapoor","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2022.03.019_b0110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00464-004-2287-z","article-title":"Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy","volume":"20","author":"Doniec","year":"2006","journal-title":"Surg Endosc Other Interv Tech"},{"key":"10.1016\/j.radonc.2022.03.019_b0115","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0360-3016(00)01427-9","article-title":"Experience with split-course external beam irradiation +\/- chemotherapy and integrated Ir-192 high-dose-rate brachytherapy in the treatment of primary carcinomas of the anal canal","volume":"49","author":"Kapp","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.03.019_b0120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02238244","article-title":"New method of radiotherapy for anal cancer with three-dimensional tumor reconstruction based on endoanal ultrasound and ultrasound-guided afterloading therapy","volume":"41","author":"Lohnert","year":"1998","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.radonc.2022.03.019_b0125","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5114\/jcb.2015.55118","article-title":"MITHRA - multiparametric MR\/CT image adapted brachytherapy (MR\/CT-IABT) in anal canal cancer: a feasibility study","volume":"5","author":"Tagliaferri","year":"2015","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.radonc.2022.03.019_b0130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13014-014-0240-4","article-title":"Interstitial high-dose rate brachytherapy as boost for anal canal cancer","volume":"9","author":"Falk","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.03.019_b0135","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98\u201311 Phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.03.019_b0140","doi-asserted-by":"crossref","unstructured":"Dietz A, Wichmann G, Wiegand S. Should We De-escalate the Treatment for HPV-Positive Tumors? Recent results cancer Res. Fortschritte der Krebsforsch. Prog. dans les Rech. sur le cancer. 2017;206:173\u2013181.","DOI":"10.1007\/978-3-319-43580-0_13"},{"key":"10.1016\/j.radonc.2022.03.019_b0145","doi-asserted-by":"crossref","unstructured":"E. Miller J. Bazan De-Escalation of Therapy for Patients with Early-Stage Squamous Cell Carcinoma of the Anus Cancers 13 9 2099.","DOI":"10.3390\/cancers13092099"},{"key":"10.1016\/j.radonc.2022.03.019_b0150","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/jcrt.JCRT_34_18","article-title":"Long-term oncologic and complication outcomes in anal cancer patients treated with radiation therapy","volume":"16","author":"Joo","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.radonc.2022.03.019_b0155","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.radonc.2018.06.007","article-title":"Determinants for local tumour control probability after radiotherapy of anal cancer","volume":"128","author":"Johnsson","year":"2018","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2022.03.019_b0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2013.05.033","article-title":"Trends in the utilization of brachytherapy in cervical cancer in the United States","volume":"87","author":"Han","year":"2013","journal-title":"Internat J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.03.019_b0165","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.03.019_b0170","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ijrobp.2013.07.035","article-title":"Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98\u201311 phase 3 trial","volume":"87","author":"Gunderson","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.03.019_b0175","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.ijrobp.2011.02.010","article-title":"Anal Canal Cancer: Management of Inguinal Nodes and Benefit of Prophylactic Inguinal Irradiation (CORS-03 Study)","volume":"82","author":"Ortholan","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.03.019_b0180","first-page":"48","article-title":"The EMBRACE II study: The outcome and prospect of two decades of evolution within GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"Potter","year":"2018","journal-title":"Clin Transl, Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.03.019_b0185","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","article-title":"Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2022.03.019_b0190","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2017.11.018","article-title":"Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer","volume":"126","author":"Sodergren","year":"2018","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022001578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022001578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:20:44Z","timestamp":1759123244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814022001578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":38,"alternative-id":["S0167814022001578"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2022.03.019","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High dose rate brachytherapy in the management of anal cancer: A review","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2022.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}